$16.02−0.68 (−4.07%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD
Dyne Therapeutics (DYN) Income Statement
Is this a real, growing, cash-generative business, or a story propped up by accounting?
Sources Company filings FilingsHow we compute thisNot investment advice
Business enginePre-revenue: no positive revenue in any year through FY25, so the growth and margin read is withheld. Worth your attention in FY25: Share count (+152.4%) and Capex step-up ($20.7M). Both visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)—
0.0
FY21→FY25CAGR —
Net income ($M)▼40.6%
−446.2
FY21→FY25CAGR —
Free cash flow ($M)▼43.8%
−423.9
capex stepped upCAGR —
Diluted EPS▼3.0%
−3.47
FY21→FY25CAGR —
What the receipts whisper · what a headline number hides
Share count
+152.4%
50.9mn → 128.4mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.
Capex step-up
$20.7M
▲772% YoY in FY25, largest jump in this window; watch free-cash-flow conversion.
What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)
Margin trend · direction beats level
This filer reports no gross profit or operating income line, so those margins are not drawn.
The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
The annual and quarterly statements are struck on share counts that differ by a factor of 0.7066, so per-share figures cannot be compared across the two tables. Each table's per-share figures are on its own share basis.
USD thousands except per-share & ratios
| Line item | TTM † | FY25 | FY24 | FY23 | FY22 | FY21 | YoY | CAGR 21→25 |
|---|---|---|---|---|---|---|---|---|
| Revenue & profitability | ||||||||
Revenue | — | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — | — |
Cost of revenue | — | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — | — |
Gross profit | — | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — | — |
Research & development | 510,233.0 | 398,333.0 | 281,406.0 | 210,762.0 | 142,760.0 | 121,308.0 | ▲41.6% | +34.6% |
Selling, general & admin | 109,907.0 | 69,851.0 | 62,480.0 | 31,400.0 | 28,202.0 | 28,717.0 | ▲11.8% | +24.9% |
Total operating expenses | 620,140.0 | 468,184.0 | 343,886.0 | 242,162.0 | 170,962.0 | 150,025.0 | ▲36.1% | +32.9% |
Operating incomefeeds ROC rank | −620,140.0 | −468,184.0 | −343,886.0 | −242,162.0 | −170,962.0 | −150,025.0 | ▼36.1% | — |
Other income, net | 15,223.0 | 21,970.0 | 26,468.0 | 6,225.0 | 2,863.0 | 734.0 | — | — |
Pretax income | −604,917.0 | −446,214.0 | −317,418.0 | −235,937.0 | −168,099.0 | −149,291.0 | ▼40.6% | — |
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings | −604,917.0 | −446,214.0 | −317,418.0 | −235,937.0 | −168,099.0 | −149,291.0 | ▼40.6% | — |
| Per share | ||||||||
Diluted EPSbuyback-sensitive | −3.56 | −3.47 | −3.37 | −3.95 | −3.23 | −2.93 | ▼3.0% | — |
Diluted shares (mn) | 181.77 | 128.44 | 94.14 | 59.68 | 51.98 | 50.90 | ▲36.4% | +26.0% |
| Margins | ||||||||
† TTM = trailing four quarters through 2026-09-30.
2 more years of statements and CSV export are on Premium.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
These lines feed the tenet checklists: see which gates passTenets →Margins & returns continue as sector-ranked ratiosStatistics →
Annual report filed 2026-03-02 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Statements normalized in our fundamentals DB · Not investment advice.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

